Thrombotic thrombocytopenic purpura: a new menace after COVID bnt162b2 vaccine

Thrombotic thrombocytopenic purpura (TTP) is a known menace in hematology and is quite rare in practice with known triggers. Lately, in the COVID-19 pandemic, hematology has seen a new pathology amongst which TTP associated with COVID-19 messenger RNA (mRNA) vaccine is unique. We report a case of a...

Descripción completa

Detalles Bibliográficos
Autores principales: Waqar, Syed Hamza Bin, Khan, Anosh Aslam, Memon, Shehzeen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Singapore 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8280631/
https://www.ncbi.nlm.nih.gov/pubmed/34264514
http://dx.doi.org/10.1007/s12185-021-03190-y
_version_ 1783722675388022784
author Waqar, Syed Hamza Bin
Khan, Anosh Aslam
Memon, Shehzeen
author_facet Waqar, Syed Hamza Bin
Khan, Anosh Aslam
Memon, Shehzeen
author_sort Waqar, Syed Hamza Bin
collection PubMed
description Thrombotic thrombocytopenic purpura (TTP) is a known menace in hematology and is quite rare in practice with known triggers. Lately, in the COVID-19 pandemic, hematology has seen a new pathology amongst which TTP associated with COVID-19 messenger RNA (mRNA) vaccine is unique. We report a case of a 69-year-old male with multiple comorbidities who presented to the hospital with severe fatigue and shortness of breath. Labs were significant for thrombocytopenia, anemia, and hemolysis with schistocytes consistent with TTP with a second dose of BNT162b2 mRNA vaccine as a likely culprit been documented.
format Online
Article
Text
id pubmed-8280631
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer Singapore
record_format MEDLINE/PubMed
spelling pubmed-82806312021-07-19 Thrombotic thrombocytopenic purpura: a new menace after COVID bnt162b2 vaccine Waqar, Syed Hamza Bin Khan, Anosh Aslam Memon, Shehzeen Int J Hematol Case Report Thrombotic thrombocytopenic purpura (TTP) is a known menace in hematology and is quite rare in practice with known triggers. Lately, in the COVID-19 pandemic, hematology has seen a new pathology amongst which TTP associated with COVID-19 messenger RNA (mRNA) vaccine is unique. We report a case of a 69-year-old male with multiple comorbidities who presented to the hospital with severe fatigue and shortness of breath. Labs were significant for thrombocytopenia, anemia, and hemolysis with schistocytes consistent with TTP with a second dose of BNT162b2 mRNA vaccine as a likely culprit been documented. Springer Singapore 2021-07-15 2021 /pmc/articles/PMC8280631/ /pubmed/34264514 http://dx.doi.org/10.1007/s12185-021-03190-y Text en © This is a U.S. government work and not under copyright protection in the U.S.; foreign copyright protection may apply 2021 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Case Report
Waqar, Syed Hamza Bin
Khan, Anosh Aslam
Memon, Shehzeen
Thrombotic thrombocytopenic purpura: a new menace after COVID bnt162b2 vaccine
title Thrombotic thrombocytopenic purpura: a new menace after COVID bnt162b2 vaccine
title_full Thrombotic thrombocytopenic purpura: a new menace after COVID bnt162b2 vaccine
title_fullStr Thrombotic thrombocytopenic purpura: a new menace after COVID bnt162b2 vaccine
title_full_unstemmed Thrombotic thrombocytopenic purpura: a new menace after COVID bnt162b2 vaccine
title_short Thrombotic thrombocytopenic purpura: a new menace after COVID bnt162b2 vaccine
title_sort thrombotic thrombocytopenic purpura: a new menace after covid bnt162b2 vaccine
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8280631/
https://www.ncbi.nlm.nih.gov/pubmed/34264514
http://dx.doi.org/10.1007/s12185-021-03190-y
work_keys_str_mv AT waqarsyedhamzabin thromboticthrombocytopenicpurpuraanewmenaceaftercovidbnt162b2vaccine
AT khananoshaslam thromboticthrombocytopenicpurpuraanewmenaceaftercovidbnt162b2vaccine
AT memonshehzeen thromboticthrombocytopenicpurpuraanewmenaceaftercovidbnt162b2vaccine

Ejemplares similares